Alternatives to OnlyRx

The async, needle-optional value play: oral or injectable semaglutide and tirzepatide from a low starting price, no video visit, ~3 days to a script — listed with its February 2026 FDA warning letter in plain view.

A fast, fully async start with a needle-free sublingual tirzepatide option and — a genuine upgrade since our last check — flat pricing stated in writing. The catch is a state list it still won't publish.

Pallas Health removes the two things that usually cost a working parent the most time: it publishes every price before intake, and it runs care asynchronously in 43 of 50 states, so there's no video appointment to wedge into a workday. Compounded semaglutide averages about $199 a month and tirzepatide $299, and unusually the genuine FDA-approved pens sit alongside them — Zepbound $1,069, Ozempic $1,299, Wegovy and Mounjaro $1,349 — all cash-pay from the same clinician. The price is flat at every dose, so a titration never produces a surprise bill, and the plan figure already contains the clinician, dose adjustments, check-ins and messaging with no membership fee. Its cancellation terms are unusually concrete: cancel free through the portal, keep access to the end of the paid period, full refund if a clinician declines you, and a $5 processing fee on a qualifying refund. The trade-offs are that billing lands every 12 weeks in $597 and $897 blocks rather than monthly, the compounding pharmacy is never named, and insurance is never billed.

Async-first compounded GLP-1 with a rarity for this list — free health coaching — at a flat one-price-all-doses rate. Fast and friendly up front; the strict, non-refundable fine print is the trade-off.

The whole price table before you hand over a detail: $175/mo semaglutide with no commitment, flat at every dose. The advertised $146 is $875 prepaid for six months — and nothing renews on its own.

One flat $195/mo plan covers compounded semaglutide, compounded tirzepatide, or a needle-free sublingual option — plus real brand-name access if you want an FDA-approved pen instead — with a women's-health-first framing and a $99 first month, though it won't name your state until you're inside the signup flow.

It shows both prices at once and says which is which: $149/mo with no commitment, $79 on a twelve-month plan. Brand-name is listed, but all three pages say coming soon.

Pepti publishes the lowest semaglutide price in this entire roster — $99 a month, flat at every titration dose, with the medication, physician review, shipping, refill management and unlimited messaging with your prescribing doctor all inside it. Tirzepatide is $199 on the same all-in, flat-at-every-dose basis. That number is low enough to deserve skepticism, so it is worth saying exactly where it comes from: Pepti states it on a dedicated cost page, repeats it in its FAQ ('we keep pricing flat and transparent at $99/mo all-in'), and prices the comparison against Hims, Henry Meds and Mochi on the same page. It names two prescribing physicians and says its medication is compounded by FDA-registered 503A or 503B pharmacies, though it never names which. The real limits are reach and format: it ships to 36 states rather than 50, it is cash-pay only and bills no insurance, and its needle-free oral GLP-1/GIP drops cost $349 — well above its own injection.

Dose-scaling pricing from $189/mo (starting dose) up to $389/mo (top tirzepatide dose), confirmed by pulling the site's own production pricing and states data directly — genuinely specific 48-state coverage (all but AL and MS) and no hidden cancellation fee found in its own Refund Policy.